<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463995</url>
  </required_header>
  <id_info>
    <org_study_id>proNICU cohort</org_study_id>
    <nct_id>NCT01463995</nct_id>
  </id_info>
  <brief_title>Prognosis in Neurological Intensive Care Unit Patients (proNICU Cohort)</brief_title>
  <acronym>proNICU</acronym>
  <official_title>Prognosis in Neurological Intensive Care Unit Patients (proNICU Cohort)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NeuroCure Clinical Research Center, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the prognostic properties of immune parameters, clinical scores,
      electrophysiological tests (eeg, ssep, emg, eng) and functional imaging for the prediction of
      functional outcome one year after treatment on a neurological intensive care unit.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive properties of immune parameters (IL6, IL10, mHLA-DR) for functional outcome one year after symptom onset</measure>
    <time_frame>one year after symptom onset</time_frame>
    <description>To evaluate of the predictive properties of immune parameters (IL6, IL10, mHLA-DR) for functional outcome one year after symptom onset</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate of the predictive properties of clinical scores for functional outcome one year after symptom onset</measure>
    <time_frame>one year after symptom onset</time_frame>
    <description>To evaluate of the predictive properties of clinical scores for functional outcome one year after symptom onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate of the predictive properties of electrophysiological measurements one year after symptom onset</measure>
    <time_frame>one year after symptom onset</time_frame>
    <description>To evaluate of the predictive properties of electrophysiological measurements one year after symptom onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate of the predictive properties of conventional (DTI) and functional imaging (resting state) one year after symptom onset</measure>
    <time_frame>one year after symptom onset</time_frame>
    <description>To evaluate of the predictive properties of conventional (DTI) and functional imaging (resting state) one year after symptom onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptome analyses</measure>
    <time_frame>one year after symptom onset</time_frame>
    <description>To perform transcriptome analyses to identify new biomarkers which may predict the one year- neurological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive properties of immune parameters in the cerebrovascular fluid for functional outcome one year after symptom onset</measure>
    <time_frame>one year after symptom onset</time_frame>
    <description>To evaluate of the predictive properties of immune parameters in the cerebrovascular fluid for functional outcome one year after symptom onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and occurence of depression in patients one year after symptom onset</measure>
    <time_frame>one year after symptom onset</time_frame>
    <description>To investigate the quality of life and the occurence of depression in patients one year after symptom onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and the occurence of depression and burnout syndrome in relatives</measure>
    <time_frame>one year after symptom onset</time_frame>
    <description>To investigate the quality of life and the occurence of depression and burnout syndrome in relatives of patients treated on the neurological intensive care unit one year after symptom onset</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Neurological Diseases</condition>
  <arm_group>
    <arm_group_label>severe neurological diseases</arm_group_label>
    <description>Patients with severe neurological diseases treated on the neurological intensive care unit</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples (serum, plasma), cerebrovascular fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with severe neurological diseases treated on a neurological intensive care unit
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe neurological disease making treatment on a neurological intensive care unit
             necessary

          -  age â‰¥ 18

          -  consent by the patient or the legal representative

        Exclusion Criteria:

          -  participation in an interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Meisel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University Berlin (Center for Stroke Research Berlin CSB &amp; NeuroCure Clinical Research Center NCRC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Meisel, MD</last_name>
    <phone>+49 30 450</phone>
    <phone_ext>560026</phone_ext>
    <email>andreas.meisel@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite University (Center for Stroke Research Berlin CSB &amp; NeuroCure Clinical Research Center NCRC)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lena Ulm, MD</last_name>
      <phone>+49 30 450</phone>
      <phone_ext>639726</phone_ext>
      <email>lena.ulm@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2011</study_first_submitted>
  <study_first_submitted_qc>November 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2011</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andreas Meisel</investigator_full_name>
    <investigator_title>Prof. Dr. med. Andreas Meisel</investigator_title>
  </responsible_party>
  <keyword>severe neurological diseases</keyword>
  <keyword>neurological intensive care unit</keyword>
  <keyword>prediction</keyword>
  <keyword>long-term outcome</keyword>
  <keyword>biomarkers</keyword>
  <keyword>prediction of long-term outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

